Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | UBE2M | P61081 | 5/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238555 | 0.88 | NOTUM (0.46) | AURKAAURKBGPR142NOTUMMAPT | |
| SCHEMBL16238490 | 0.88 | AURKA (0.40) | AURKAAURKBIDH2GPR142NOTUM | |
| Trifluoroacetic Acid SCHEMBL16238799 | 0.87 | NOTUM (0.44) | AURKAAURKBIDH2GPR142NOTUM | |
| SCHEMBL16249982 | 0.86 | AURKA (0.38) | AURKAAURKBGPR142NOTUMMAPT | |
| SCHEMBL19865067 | 0.84 | NOTUM (0.47) | AURKAAURKBGPR142NOTUMMEN1 | |
| SCHEMBL16238397 | 0.83 | AURKA (0.37) | AURKAAURKBGPR142NOTUMALK | |
| SCHEMBL16249981 | 0.82 | HDAC3 (0.40) | AURKAAURKBNOTUMALK | |
| SCHEMBL17618783 | 0.82 | MEN1 (0.47) | IDH2MAPTMEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL16754672 | 0.81 | HDAC3 (0.40) | AURKAAURKBNOTUMALK | |
| SCHEMBL17601648 | 0.81 | IDH2 (0.36) | AURKAAURKBUBE2MDCUN1D1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | AURKA 2147/4885AURKB 887/4885UBE2M 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.